PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein
| Specifications | |
|---|---|
| Category: | Fluorescent labeled protein |
| Molecular Weight: | 36.3 kDa and 13.8 kDa |
| Tag: | C-10×His |
| Label / Conjugate: | PE Labeled |
| Source: | PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (HL1-HP2E5) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & SLLMWITQC). |
| Purity: | N/A |
| Endotoxin Level: | N/A |
| Format: | Powder |
| Additional Information | |
|---|---|
| Organism: | Human |
| Accn. No.: | AAA59606.1 |
Sequence Information
Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide
Background
NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
Price
849,00 €
